Qiagen N.V. (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages

Shares of Qiagen N.V. (NYSE:QGEN) have been assigned a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $43.51.

QGEN has been the topic of several research analyst reports. Stifel Nicolaus set a $40.00 price objective on Qiagen in a research note on Friday, August 7th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. Finally, JPMorgan Chase & Co. upped their price target on shares of Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

Institutional Investors Weigh In On Qiagen

Large investors have recently modified their holdings of the stock. Manchester Capital Management LLC purchased a new position in Qiagen in the 4th quarter worth approximately $42,000. Hilltop National Bank purchased a new position in shares of Qiagen in the second quarter valued at $50,000. Integrated Wealth Concepts LLC purchased a new position in shares of Qiagen in the second quarter valued at $59,000. Allworth Financial LP grew its holdings in Qiagen by 20.8% during the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after purchasing an additional 317 shares in the last quarter. Finally, denkapparat Operations GmbH acquired a new stake in Qiagen during the 2nd quarter valued at $105,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Performance

Qiagen stock opened at $44.74 on Friday. Qiagen has a fifty-two week low of $32.53 and a fifty-two week high of $57.81. The company has a market capitalization of $9.22 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 4.18 and a beta of 0.61. The stock has a fifty day moving average of $43.10 and a two-hundred day moving average of $39.97. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period in the previous year, the firm posted $0.60 EPS. Qiagen’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts anticipate that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.